Analysis of SARS-CoV-2 Genomes from West Java, Indonesia.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
18 10 2021
Historique:
received: 18 09 2021
revised: 12 10 2021
accepted: 14 10 2021
entrez: 26 10 2021
pubmed: 27 10 2021
medline: 11 11 2021
Statut: epublish

Résumé

West Java Health Laboratory (WJHL) is one of the many institutions in Indonesia that have sequenced SARS-CoV-2 genome. Although having submitted a large number of sequences since September 2020, however, these submitted data lack advanced analyses. Therefore, in this study, we analyze the variant distribution, hotspot mutation, and its impact on protein structure and function of SARS-CoV-2 from the collected samples from WJHL. As many as one hundred sixty-three SARS-CoV-2 genome sequences submitted by West Java Health Laboratory (WJHL), with collection dates between September 2020 and June 2021, were retrieved from GISAID. Subsequently, the frequency and distribution of non-synonymous mutations across different cities and regencies from these samples were analyzed. The effect of the most prevalent mutations from dominant variants on the stability of their corresponding proteins was examined. The samples mostly consisted of people of working-age, and were distributed between female and male equally. All of the sample sequences showed varying levels of diversity, especially samples from West Bandung which carried the highest diversity. Dominant variants are the VOC B.1.617.2 (Delta) variant, B.1.466.2 variant, and B.1.470 variant. The genomic regions with the highest number of mutations are the spike, NSP3, nucleocapsid, NSP12, and ORF3a protein. Mutation analysis showed that mutations in structural protein might increase the stability of the protein. Oppositely, mutations in non-structural protein might lead to a decrease in protein stability. However, further research to study the impact of mutations on the function of SARS-CoV-2 proteins are required.

Identifiants

pubmed: 34696527
pii: v13102097
doi: 10.3390/v13102097
pmc: PMC8538575
pii:
doi:

Substances chimiques

Coronavirus Nucleocapsid Proteins 0
ORF3a protein, SARS-CoV-2 0
Phosphoproteins 0
Spike Glycoprotein, Coronavirus 0
Viral Proteins 0
Viroporin Proteins 0
nucleocapsid phosphoprotein, SARS-CoV-2 0
spike protein, SARS-CoV-2 0
Coronavirus RNA-Dependent RNA Polymerase EC 2.7.7.48
NSP12 protein, SARS-CoV-2 EC 2.7.7.48
Coronavirus Papain-Like Proteases EC 3.4.22.2
papain-like protease, SARS-CoV-2 EC 3.4.22.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Commun Biol. 2021 Feb 15;4(1):228
pubmed: 33589648
Bioinformatics. 2014 Oct 15;30(20):2981-2
pubmed: 24996895
Bioinformatics. 2011 Jun 15;27(12):1711-2
pubmed: 21505037
J Mol Biol. 2016 Feb 22;428(4):720-725
pubmed: 26410586
PLoS One. 2020 Dec 22;15(12):e0243703
pubmed: 33351801
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Bioinformatics. 2016 Dec 1;32(23):3676-3678
pubmed: 27503228
Nat Commun. 2019 May 28;10(1):2342
pubmed: 31138817
Sci Rep. 2020 Jul 2;10(1):10895
pubmed: 32616763
Pathogens. 2020 Oct 10;9(10):
pubmed: 33050463
Curr Protoc Bioinformatics. 2015 Dec 17;52:5.8.1-5.8.15
pubmed: 26678386
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
J Med Virol. 2021 Apr;93(4):2132-2140
pubmed: 33090512
Sci Rep. 2021 Mar 23;11(1):6625
pubmed: 33758205
Cell Mol Immunol. 2021 Mar;18(3):746-748
pubmed: 33473190
Nat Med. 2021 Sep;27(9):1495-1496
pubmed: 34400842
Infect Dis Rep. 2021 Jun 21;13(2):582-596
pubmed: 34205538
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Antiviral Res. 2018 Jan;149:58-74
pubmed: 29128390

Auteurs

Azzania Fibriani (A)

Bandung Institute of Technology, Bandung, West Java 40132, Indonesia.

Rebecca Stephanie (R)

Bandung Institute of Technology, Bandung, West Java 40132, Indonesia.

Afifah Alifia Alfiantie (AA)

Bandung Institute of Technology, Bandung, West Java 40132, Indonesia.

Agust Leo Fany Siregar (ALF)

Bandung Institute of Technology, Bandung, West Java 40132, Indonesia.

Gusti Ayu Prani Pradani (GAP)

Bandung Institute of Technology, Bandung, West Java 40132, Indonesia.

Nicholas Yamahoki (N)

Bandung Institute of Technology, Bandung, West Java 40132, Indonesia.

William Steflandel Purba (WS)

Bandung Institute of Technology, Bandung, West Java 40132, Indonesia.

Cut Nur Cinthia Alamanda (CNC)

West Java Health Laboratory, Bandung, West Java 40161, Indonesia.

Ema Rahmawati (E)

West Java Health Laboratory, Bandung, West Java 40161, Indonesia.

Rifky Waluyajati Rachman (RW)

West Java Health Laboratory, Bandung, West Java 40161, Indonesia.

Rini Robiani (R)

West Java Health Laboratory, Bandung, West Java 40161, Indonesia.

Ryan Bayusantika Ristandi (RB)

West Java Health Laboratory, Bandung, West Java 40161, Indonesia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH